Vessi Medical takes a new approach in the treatment of superficial bladder cancer. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.
Vessi Medical’s minimally invasive non-muscle-invasive bladder cancer (NMIBC) solution provides an office-based therapeutic alternative to surgery. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.
The Vessi Medical system consists of a standalone console and a disposable catheter that is inserted into the bladder similar to existing intravesical (inside the bladder) techniques.
Currently, surface cryotherapy is used extensively in many applications, and it has been known to be highly effective in destroying surface lesions.
The market seeks an effective treatment for superficial bladder cancer that offers reduced recurrence rates, reduced side effects, improved patient outcomes, and lower health care costs.
Founded: Joined Trendlines Medical July 2017
Stage: Technology development
Investor: The Trendlines Group
IP: National phase and PCT
Non-muscle-invasive bladder cancer (NMIBC), also known as superficial bladder cancer, is found on the surface of the inside lining of the bladder, and accounts for ~75% of new patients with bladder cancer. In cases of high-risk superficial bladder cancer, treatment involves intravesical therapy in which an immunotherapy or chemotherapy drug is inserted directly into the bladder via a catheter. These therapy modalities cause severe side effects and have limited outcomes. Unfortunately, due to high recurrence rates, many patients undergo bladder removal.
Reports state that bladder cancer has the highest cost per patient of all cancers, and that 43% of all bladder removals begin with superficial cancer (European Association of Urology. 2012. Guidelines on Bladder Cancer Muscle-invasive and Metastatic.)
NMIBC affects 2 million people globally with 300,000 new cases reported yearly (Turk J Urol. March 2016 ).
Vessi Medical estimates its immediate U.S. addressable market at $400 million per year with a global market potential at over $1 billion annually and estimates its global market potential at over $1 billion annually.
Minimally invasive treatment of heart valve disease
A more efficient ablation catheter to treat atrial fibrillation
Preventing the development of pressure sores
Novel treatment for vertebral compression fractures
Preventing catheter-associated urinary tract infections (CAUTIs)
Wireless, wearable vital sign monitoring system
Endoscopic ultrasound fine needle biopsy system